Catalyst Event
Astrazeneca PLC (AZN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/16/2026, 12:00:00 AM
AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy expected to be approved in the EU for resectable, early-stage gastric and GEJ cancers on March 16, 2026. Regulatory approval for a major indication is estimated to result in a >5% price impact.
Korean Translation
아스트라제네카의 임핀지(더발루맙) 병용요법이 초기 위암 및 위식도 접합부암 치료제로 2026년 3월 16일 유럽연합(EU) 승인 예정됨. 주요 적응증 승인은 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Q1 2026 earnings release scheduled. This is an estimated date based on past reporting schedules.
5/28/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q1 2026 earnings release with adjusted EPS guidance of $1.12 to $1.18, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend ex-date of $0.63 per share on 2026-04-15, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, a 3% increase, will have its ex-dividend date on March 27, 2026. The dividend is payable on April 10, 2026. A 1% price impact is estimated due to the dividend increase, scheduled.
3/27/2026, 12:00:00 AM